RecruitingNot ApplicableNCT06498349

Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl

A Randomized Controlled Trial of Bilateral Subthalamic Stimulation in Patients With Parkinson's Disease and Impulse Control Disorders


Sponsor

University of Kiel

Enrollment

60 participants

Start Date

Sep 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The focus of the study is on patients Parkinson's disease showing as well behavioral disorders that can be described as pathological and are summarized under the term impulse control disorder (ICD). Changes in behavior and also pathological disorders are a common side effect of treatment for Parkinson's disease. The goal of this academic study is to compare the effect of surgical (deep brain stimulation, DBS) treatment combined with a coordinated and adapted best medical treatment (BMT) to be compared with the effect of optimized best medical treatment (BMT) alone. The stimulation arm (DBS+BMT) as well as the medication arm (BMT only) will be monitored according to clinical routine. Participants will have to agree to be randomly assigned to either deep brain stimulation in combination with the best medical treatment (DBS group) or the best medical treatment alone (BMT group). Participants will have to come regularly according to clinical routine to the clinic and complete various questionaires and scales for the study.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria10

  • Age at the time of enrollment: ≤ 70 years
  • Diagnosis of PD according to MDS clinical diagnostic criteria
  • Onset of first PD motor symptoms ≥ 4 years
  • Moderate or severe impulse control disorder or related behavioral disorders according to Ardouin, with at least 1 score greater than or equal to 3 (or at least 2 scores greater than or equal to 2) on the Ardouin behaviour scale with the following items considered to reflect ICBDs or related behaviors: pathological gambling, hypersexuality, shopping, eating, hobbyism, punding and compulsive medication use
  • MDS-UPDRS III improvement of ≥ 30% in the standardized levodopa test or classical Parkinsonian tremor at rest
  • Adaptation of medical therapy has been attempted
  • MoCA ≥ 24 in the meds on condition
  • BDI-II score \< 20 in the meds on condition, or Patients with moderately severe depression with a BDI-II between 20 and 28 points, strict consideration must be made with the involvement of a psychiatrist. Patients must be willing and able to comply this.
  • Patients able to understand the study requirements and the treatment procedures
  • Written informed consent before any study-specific tests or procedures are performed

Exclusion Criteria13

  • Surgical contraindications to undergo DBS operation
  • Ongoing severe depression (BDI-II \> 28)
  • suicidal ideation (item 9 of BDI-II \> 1)
  • Dementia (MoCA \< 24) in the meds on condition
  • Any prior movement disorder treatments that involved intracranial surgery/ablation or intracranial device implantation
  • Any other active implanted device that is likely to interfere with the implantation or functioning of the DBS system
  • Simultaneous participation in another clinical trial targeting or potentially interfering with ICD
  • Any history of recurrent seizures or haemorrhagic stroke
  • Fertile women not using adequate contraceptive methods
  • Any terminal illness with significantly reduced life expectancy which exclude DBS implantation according to standard clinical care
  • A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception
  • Any impairment that would limit subject's ability to participate in the study and perform study procedures
  • Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints

Interventions

PROCEDUREbilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment

according to widely accepted expert consensus paper

DRUGbest medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations

according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.


Locations(12)

University Hospital Cologne

Cologne, Germany

University Hospital Carl Gustav Carus

Dresden, Germany

University Hospital Duesseldorf

Düsseldorf, Germany

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

University Hospital Schleswig-Holstein (UKSH), Campus Kiel

Kiel, Germany

University Hospital of Giessen and Marburg (UKGM), Campus Marburg

Marburg, Germany

Charité Campus Mitte

Mitte, Germany

University Hospital Tuebingen

Tübingen, Germany

University Hospital Wuerzburg

Würzburg, Germany

Amsterdam University Medical Center

Amsterdam, Netherlands

University Hospital of Bern (Inselspital)

Bern, Switzerland

University Hospital Zuerich (USZ)

Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06498349


Related Trials